← 返回前沿论文

鼻咽癌发生背景下的 EB 病毒特异性功能性抗体特征

英文原题:Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development.

PubMed 2025/11/18(内容时间) Med Q1 · IF 13.3(JCR 2025)

研究概要

本研究为EBV特异性抗体作为NPC进展的预测性生物标志物提供了有价值的见解,为改善疾病管理提供了机会。

研究思路结论见上方概要

在流行区,鼻咽癌(NPC)与EB病毒(EBV)感染密切相关。EBV特异性免疫球蛋白(Ig)A和IgG滴度已用于诊断和预后,但其在预测和保护方面的全部潜力仍不清楚。

我们分析了353名个体的样本,包括诊断时或诊断前数年的鼻咽癌患者、匹配对照,以及来自台湾鼻咽癌多发家系的家庭成员,另外还有来自新加坡的50名具有生存数据的鼻咽癌患者。我们采用了系统血清学方法,这是一种综合评估抗体亚类、同种型、Fcγ受体(FcγR)结合,以及补体沉积、细胞吞噬和自然杀伤(NK)细胞活化等效应功能的全面方法。

与对照组相比,NPC患者表现出抗体水平、Fc R结合和Fc效应功能的广泛扩增,尤其是中性粒细胞吞噬作用和补体沉积。在NPC发病前,个体表现出EBV特异性IgM水平升高以及Fc RIIA和Fc RIIIB结合增强,提示对病毒活动的早期免疫应答。IgM似乎是NPC的潜在相关性标志物。相比之下,对照组表现出IgG2水平升高和Fc RIIB结合增加,表明炎症反应较低。在单个抗体水平上,对照组表现出更强的Fc效应功能,提示其在预防NPC中具有保护作用。此外,我们鉴定出一个与治疗后生存相关的多变量抗体特征。

展开英文摘要原文

BACKGROUND: Nasopharyngeal carcinoma (NPC) in endemic areas is strongly linked to Epstein-Barr virus (EBV) infection. EBV-specific immunoglobulin (Ig)A and IgG titers have been used for diagnosis and prognosis, but their full potential for prediction and protection remains unclear. METHODS: We analyzed samples from 353 individuals, including patients with NPC at diagnosis or patients with NPC years prior to diagnosis, matched controls, and family members from NPC multiplex families from Taiwan, along with 50 patients with NPC from Singapore with survival data. We used systems serology, a comprehensive approach to assess antibody subclass, isotype, and fragment crystallizable gamma receptor (Fc R) binding, along with effector functions such as complement deposition, cellular phagocytosis, and natural killer (NK) cell activation. FINDINGS: Patients with NPC showed a broad expansion of antibody levels, Fc R binding, and Fc effector functions, especially neutrophil phagocytosis and complement deposition, compared to controls. Prior to NPC onset, individuals exhibited elevated EBV-specific IgM levels and higher Fc RIIA and Fc RIIIB binding, suggesting an early immune response to viral activity. IgMs appeared as potential correlative markers for NPC. In contrast, controls showed increased IgG2 levels and Fc RIIB binding, indicating lower inflammatory responses. On a per-antibody level, controls exhibited stronger Fc effector functions, suggesting a protective role in preventing NPC. Additionally, we identified a multivariate antibody signature associated with survival after treatment. CONCLUSIONS: This study provides valuable insights into EBV-specific antibodies as predictive biomarkers of NPC progression, offering opportunities for improved disease management. FUNDING: This work was supported by the Ragon Institute of Mass General, MIT, and Harvard with support from the National Cancer Institute (CA264646 to E.W.N.).

论文信息

作者
Roy V、Kellman BP、Hsu WL、Nziza N、Parker L、Germosen D、Bonifer R、Pfeiffer RM
第一作者单位
Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA; Institute of Virology, University Hospital Bonn, Bonn, Germany.United Kingdom
通讯作者单位
Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. Electronic address: bjulg@mgh.harvard.edu.United Kingdom
文献类型
美国 NIH 资助研究 · 美国 NIH 院内研究
期刊
Med (New York, N.Y.)2026 Jan 9
原文标识
PubMed 41260224 · DOI 10.1016/j.medj.2025.100925